People: Sequenom Inc (SQNM.OQ)

SQNM.OQ on NASDAQ Stock Exchange Global Select Market

3.79USD
12:32pm EDT
Price Change (% chg)

$0.06 (+1.61%)
Prev Close
$3.73
Open
$3.76
Day's High
$3.83
Day's Low
$3.76
Volume
160,079
Avg. Vol
399,214
52-wk High
$4.74
52-wk Low
$1.65

Search Stocks

Summary

Name Age Since Current Position

Harry Hixson

75 2014 Chairman of the Board

William Welch

52 2014 President, Chief Executive Officer, Chief Operating Officer

Carolyn Beaver

56 2014 Chief Financial Officer, Chief Accounting Officer, Vice President

R. William Bowen

61 2012 Senior Vice President, General Counsel, Secretary

Michael Monko

54 2011 Senior Vice President - Bioscience

Robin Weiner

58 2010 Senior Vice President - Quality and Regulatory Affairs

Dirk van den Boom

43 2014 Chief Scientific & Strategy Officer

Richard Lerner

75 2010 Lead Independent Director

Myla Lai-Goldman

56 2012 Director

Ronald Lindsay

66 2013 Director

Kenneth Buechler

60 2009 Independent Director

John Fazio

70 2007 Independent Director

David Pendarvis

55 2009 Independent Director

Charles Slacik

60 2011 Independent Director

Donna Nichols

2013 IR Contact Officer

Biographies

Name Description

Harry Hixson

Dr. Harry F. Hixson, Jr., Ph.D., is Chairman of the Board of Sequenom, Inc. Dr. Hixson is no longer Chief Executive Officer of the Company, effective June 10, 2014. He served as a director of BrainCells, Inc., from December 2003 to February 2011, where he also served as Chief Executive Officer from July 2004 until September 2005. Dr. Hixson served as Chief Executive Officer of Elitra Pharmaceuticals, Inc., a biopharmaceutical company focused on anti-infective drug development, from February 1998 until May 2003. He served as President and Chief Operating Officer of Amgen Inc., and as a member of its board of directors from 1988 to 1991. Prior to Amgen, Dr. Hixson held various management positions with Abbott Laboratories, including Vice President, Diagnostic Products Business Group, and Vice President, Research and Development, in the Diagnostics Division. Dr. Hixson also is a director of Arena Pharmaceuticals, Inc., and from September 2006 until May 2010 served as a director of Infinity Pharmaceuticals, Inc., and from February 2009 until September 2010 served as a director of Novabay Pharmaceuticals. Dr. Hixson received his Ph.D. in Physical Biochemistry from Purdue University and an M.B.A. from the University of Chicago.

William Welch

Mr. William J. Welch has been President, Chief Executive Officer, Chief Operating Officer of Sequenom Inc. Effective June 10, 2014, Mr. Welch will serve as the Chief Executive Officer. Prior to joining to the company, from September 2009 to January 2011, Mr. Welch was a consultant to molecular diagnostic companies in the personalized medicine sector. From August 2005 to September 2009, Mr. Welch was Senior Vice President and Chief Commercial Officer at Monogram Biosciences, a bioscience laboratory services company. Prior to Monogram, Mr. Welch held commercial management positions at La Jolla Pharmaceuticals and Dade Behring MicroScan, and initially entered the healthcare field with Abbott Laboratories where he held progressive management positions, including General Manager. Mr. Welch received his M.B.A from Harvard University and a B.S. with honors in chemical engineering from the University of California, Berkeley.

Carolyn Beaver

Ms. Carolyn Beaver has been Vice Chief Financial Officer, Chief Accounting Officer, Vice President of Sequenom Inc. She has been appointed as Chief Financial Officer effective June 10, 2014. Since its acquisition by Danaher Corp. in June 2011, Ms. Beaver has continued to serve at Beckman Coulter, Inc. as the Corporate Vice President, Controller. From 1987 until 2002, Ms. Beaver was a partner with KPMG LLP. Ms. Beaver also currently serves as a director of Commerce National Bank, a position she has held since 2005. Ms. Beaver holds a B.S. in Accounting from California State Polytechnic University, Pomona.

R. William Bowen

Mr. William Bowen is Senior Vice President, General Counsel, Secretary of Sequenom Inc. Mr. Bowen previously served as Senior Vice President, General Counsel and Secretary of Gen-Probe Incorporated, or Gen-Probe, a molecular diagnostic company focused on infectious disease, from June 1997 to August 2012. Prior to Gen-Probe, Mr. Bowen was a business litigation partner with the law firm of Luce, Forward, Hamilton & Scripps in San Diego, California. Mr. Bowen received his J.D. and a B.S. in commerce from the University of Virginia.

Michael Monko

Mr. Michael Monko, M.B.A., is Senior Vice President, Bioscience of Sequenom Inc. He previously served as our senior vice president, sales and marketing since August 2006. Mr. Monko served as vice president of sales for the organization that is now the diagnostics strategic business unit of Millipore, a bioscience research and biopharmaceutical manufacturing supplier, from 2005 to July 2006. Previously, he served 19 years in various sales roles at Invitrogen Corporation (now Life Technologies, Corp.), a biotechnology tools company. Mr. Monko received his M.B.A. from Babson College.

Robin Weiner

Ms. Robin G. Weiner, MBA., serves as Senior Vice President - Quality and Regulatory Affairs of Sequenom Inc. Prior to joining to the company, Ms. Weiner was an independent regulatory consultant to biotechnology companies, focusing on regulatory strategy, product submissions and quality management systems. From 2004 to 2007, Ms. Weiner served as vice president regulatory and government affairs at Biosite Incorporated, a medical device company, and was responsible for leading Biosite's worldwide product approvals and regulatory compliance activities. Ms. Weiner received her M.B.A. in business administration from National University and a B.A. from the University of California, San Diego.

Dirk van den Boom

Dr. Dirk van den Boom, Ph.D., is Chief Scientific & Strategy Officer of Sequenom Inc., effective June 30, 2014. Dr. van den Boom has served as the Executive Vice President, Research and Development and Chief Technology Officer since December 2012 and was named Chief Scientific Officer in January 2014. Previously he had served as Senior Vice President of Research and Development since August 2010 and as Vice President, Research and Development from October 2009 to August 2010. Dr. van den Boom joined Sequenom in 1998 in the company's Hamburg offices, subsequently serving in various management roles within our research and development department. Dr. van den Boom has co-authored more than 50 scientific articles and is inventor on 48 patents/patent applications. Dr. van den Boom received his Ph.D. in Biochemistry/Molecular Biology from the University of Hamburg where he focused on various aspects of nucleic acid analysis with mass spectrometry.

Richard Lerner

Professor Dr. Richard A. Lerner, M.D., serves as Lead Independent Director of Sequenom Inc. Dr. Lerner served as President of the Scripps Research Institute, a private, non-profit biomedical research organization from 1986 to January 2012, and since then has served and continues to serve as Institute Professor. Dr. Lerner received the Wolf Prize in Chemistry in 1994, the California Scientist of the Year Award in 1996, the Paul Ehrlich and Ludwig Darmstaedter Prize in 2003, and the Prince of Asturias Award in 2012 for his achievements in the development of catalytic antibodies and combinatorial antibody libraries. Dr. Lerner is a member of the Royal Swedish Academy of Sciences and the National Academy of Sciences. Dr. Lerner served as a director of Kraft Foods, Inc. from 2005 to March 2012 and currently serves as a director of Opko Health, Inc., Teva Pharmaceutical Industries Ltd., and IntraCellular Therapies. Dr. Lerner received his M.D. from Stanford Medical School.

Myla Lai-Goldman

Dr. Myla P. Lai-Goldman, M.D., has been appointed as Director of Sequenom, Inc., effective September 11, 2012. Since September 2008, she has been the managing partner of Personalized Science, LLC, a consulting company she founded that is focused on innovative diagnostics for patients’ unmet clinical needs. Dr. Lai-Goldman is also the Chief Executive Officer and President of GeneCentric Diagnostics, Inc., a molecular diagnostics company focused on developing and commercializing assays that enable oncologists and their patients to make informed, individualized, treatment decisions. Dr. Lai-Goldman has been with GeneCentric Diagnostics, Inc., since June 2011. Dr. Lai-Goldman is also a venture partner with Hatteras Venture Partners, as position she has held since August 2011. From June 2009 to December 2010, Dr. Lai-Goldman was Chief Executive Officer and Chief Scientific Officer of CancerGuide Diagnostics, Inc., a life science company focused on the development and commercialization of genomic-based clinical and pharmaceutical cancer tests and services. From 1990 to December 2008, Dr. Lai-Goldman served in various roles at Laboratory Corporation of America Holdings and its predecessor company, Roche Biomedical Laboratories, a clinical laboratory company, including Executive Vice President, Chief Medical Officer, and Chief Scientific Officer. Dr. Lai-Goldman is a recognized author and speaker on clinical diagnostics. Dr. Lai-Goldman received her B.S. in biology from the University of Pennsylvania and her medical degree from Columbia University. Dr. Lai-Goldman completed a pathology residency and surgical pathology fellowship at The University of California, Los Angeles, and a hematopathology fellowship at The University of North Carolina, Chapel Hill. Dr. Lai-Goldman is board certified in anatomic and clinical pathology.

Ronald Lindsay

Dr. Ronald M. Lindsay, Ph.D., is Director of Sequenom Inc. He is no longer Executive Vice President - Strategic Planning of the Company effective December 31, 2013. He previously served as interim Senior Vice President of Research and Development from September 2009 until August 2010. Dr. Lindsay has served as a member of Board of Directors since 2003. He currently operates Milestone Consulting, a biopharmaceutical consulting firm. Dr. Lindsay served as Vice President, Research and Development, and Chief Science Officer of diaDexus Inc., a biotechnology company, from 2000 to January 2004. From 1997 through 2000, Dr. Lindsay served in various senior management roles with Millennium Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 to 1997, Dr. Lindsay served in various roles with Regeneron Pharmaceuticals Inc., of which he was a founding scientist. He is a director of Arqule Inc., and HistoRx Inc. Dr. Lindsay received his Ph.D. in Biochemistry from the University of Calgary.

Kenneth Buechler

Dr. Kenneth F. Buechler, Ph.D., serves as an Independent Director of Sequenom Inc., since December 2009. Dr. Buechler was President and Chief Scientific Officer of Biosite Incorporated, a provider of diagnostic products and antibody development technologies, from 2003 to 2007, and prior to that was a co-founder and held roles as Director of Chemistry and Vice-President of Research and Development from 1988 to 2003. Prior to forming Biosite, Dr. Buechler was a senior research scientist for the diagnostics research and development group at Hybritech Incorporated, a biotechnology company located in San Diego. Dr. Buechler served on the board of directors of Adnavance, Inc. from March 2008 until April 2010. Dr. Buechler currently serves on the board of directors of Quidel Corp., Sotera Wireless Inc., and Astute Medical Inc. Dr. Buechler received his Ph.D in biochemistry from Indiana University.

John Fazio

Mr. John A. Fazio serves as an Independent Director of Sequenom Inc., since 2007. Mr. Fazio is a former senior general practice partner of PricewaterhouseCoopers, a global accounting and professional services company. Mr. Fazio retired from PricewaterhouseCoopers in 2000 following 35 years of service during which he held a variety of senior positions in accounting, auditing, consulting, and administration. Currently, Mr. Fazio serves on the board of directors of Heidrick & Struggles International, Inc. Mr. Fazio served on the board of directors of Imclone Systems, Inc. from February 2003 until April 2006, and served on the board of directors of Dendrite International, Inc. from March 2003 until August 2007. Mr. Fazio is a member of the American Institute of Certified Public Accountants and the Institute of Management Accountants and holds an M.A. from Ohio State University.

David Pendarvis

Mr. David Pendarvis serves as an Independent Director of Sequenom Inc., since December 2009. Mr. Pendarvis is Chief Administrative Officer, Global General Counsel and Secretary of ResMed Inc., a medical device company focused on sleep-disordered breathing. He has been with ResMed since 2002. From 2000 until 2002, Mr. Pendarvis was a partner in the law firm of Gray Cary Ware & Freidenrich LLP. Until 2000 he was a partner with Gibson, Dunn & Crutcher LLP, where he began working in 1986. From 1984 until 1986 he was a law clerk to the Hon. J. Lawrence Irving, US District Judge, Southern District of California. Mr. Pendarvis received his J.D. from the University of Texas School of Law and his M.S. in executive leadership from the University of San Diego.

Charles Slacik

Mr. Charles P. Slacik serves as an Independent Director of Sequenom Inc., since June 15, 2011. Mr. Slacik was Chief Financial Officer and Senior Vice President of Finance of Beckman Coulter Inc., a leading manufacturer of biomedical testing instrument systems, tests and supplies, from October 2006 to September 2011 and was responsible for all aspects of financial management and information technology. From 2003 to 2006, Mr. Slacik served as Executive Vice President and Chief Financial Officer of Watson Pharmaceuticals, Inc., an integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, brand and biologic pharmaceutical products. From 1999 to 2003, Mr. Slacik served as Senior Vice President and Chief Financial officer of C.R. Bard, Inc., a developer and manufacturer of medical technologies in the fields of vascular, urology, oncology and surgical specialty products. Currently, Mr. Slacik serves on the board of directors of STAAR Surgical Company. Mr. Slacik earned a Bachelor of Science degree in accounting and finance from the University of Connecticut and is a Certified Public Accountant.

Donna Nichols

Search Stocks